[ Bone and cartilage destruction in RA and its intervention. Disease-modifying antirheumatic drugs].
The primary goal in the treatment of rheumatoid arthritis (RA) is to maintain good quality of life by preventing joint destruction and avoiding disability. For this purpose, all patients with the diagnosis of RA should be treated by disease-modifying antirheumatic drugs (DMARDs) including biologic DMARDs and non-biologic DMARDs. All DMARDs are expected to prevent the progression of bone and cartilage destruction of RA patients from the results of in vitro research, and prevention of joint destruction is confirmed in vivo in all biologic DMARDs, but not in all non-biologic DMARDs. In this chapter, we would like to review the results of basic researches and clinical studies to demonstrate the prevention of joint destruction by non-biologic DMARDs that have been frequently used I daily practice.
Institute of Rheumatology, Tokyo Women's Medical University, Japan.
Naomi
N
Ichikawa
Hisashi
H
Yamanaka
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D001842:Bone and Bones / Q000473:pathology; D002356:Cartilage / Q000469:parasitology; D002986:Clinical Trials as Topic; D003545:Cysteine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use; D007596:Joints / Q000473:pathology; D000077339:Leflunomide; D008727:Methotrexate / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
D018501:Antirheumatic Agents; D007555:Isoxazoles; D012460:Sulfasalazine; D000077339:Leflunomide; D003545:Cysteine; C026535:bucillamine; D016559:Tacrolimus; D008727:Methotrexate